BIOPHARMACEUTICAL FORMULATION OF ANTI-PD-1, ANTI-PD-L1, AND ANTI-VEGFR THERAPEUTIC MONOCLONAL ANTIBODIES AND METHOD FOR TREATING NSCLC BY INHALATION
This invention relates to pharmaceutical formulations of therapeutic monoclonal antibody drugs and pharmaceutically acceptable excipients and a novel therapeutic strategy for the treatment of lung cancers including metastatic NSCLC by administration of such formulations using a soft mist inhaler and/or nebulizer. The pharmaceutical formulations comprise (a) a therapeutic monoclonal antibody selected from the group consisting of pembrolizumab, atezolizumab, nivolumab, durvalumab, and bevacizumab, (b) water, and (c) a buffer. The pharmaceutical formulations are delivered locally to the lungs by inhalation for treatment of cancer.
1 . A pharmaceutical formulation suitable for administration by soft mist inhalation or nebulization comprising:
(a) a therapeutic monoclonal antibody in a concentration of from about 1 mg/ml to about 100 mg/ml,
(b) water, and
(c) a buffer,
wherein the therapeutic monoclonal antibody is selected from the group consisting of pembrolizumab, atezolizumab, nivolumab, durvalumab, and bevacizumab.
2 . A method of administering the pharmaceutical formulation of claim 1 comprising inhalation via an inhalation device selected from a soft mist inhalation device and a nebulization device.
3 . The pharmaceutical formulation of claim 1 wherein
the therapeutic monoclonal antibody is pembrolizumab in a concentration of from about 1 mg/ml to about 25 mg/ml;
the buffer comprises from about 1 mM to about 10 mM of L-histidine, from about 50 mM to about 200 mM sucrose, and from about 0.04 mM to about 0.15 mM polysorbate 80;
the pharmaceutical formulation has a pH of from about 5.5 to about 5.8; and
the pharmaceutical formulation is stable for at least about 12 months when stored under refrigerated conditions at about 2° C. to about 8° C.
4 . The pharmaceutical formulation of claim 1 wherein
the therapeutic monoclonal antibody is atezolizumab in an amount of from about 10 mg/ml to about 65 mg/ml;
the buffer comprises from about 50 mM to about 450 mM of L-histidine, from about 500 mM to about 2450 mM sucrose, from about 1 mM to about 10 mM polysorbate 20, and from about 60 mM to about 300 mM of glacial acetic acid;
the pharmaceutical formulation has a pH of from about 5.8 to about 6; and
the pharmaceutical formulation is stable for at least about 12 months when stored under refrigerated conditions at about 2° C. to about 8° C.
5 . The pharmaceutical formulation of claim 1 wherein
the therapeutic monoclonal antibody is nivolumab in an amount of from about 5 mg/ml to about 10 mg/ml;
the buffer comprises from about 0.05 mM to about 200 mM of polysorbate 80, from about 10 mM to about 30 mM sodium citrate dihydrate, from about 20 mM to about 60 sodium chloride, and from about 50 mM to about 200 mM of mannitol, and from about 0.005 mM to about 0.025 mM pentetic acid;
the pharmaceutical formulation has a pH of about 6; and
the pharmaceutical formulation is stable for at least about 12 months when stored under refrigerated conditions at about 2° C. to about 8° C.
6 . The pharmaceutical formulation of claim 1 wherein
the therapeutic monoclonal antibody is durvalumab in an amount of from about 10 mg/ml to about 55 mg/ml;
the buffer comprises from about 1 mM to about 15 mM of L-histidine, from about 0.03 mM to about 0.2 mM polysorbate 80, from about 1 mM to about 15 L-histidine hydrochloride monohydrate, and from about 50 mM to about 300 mM of trehalose dihydrate;
the pharmaceutical formulation has a pH of about 6; and
the pharmaceutical formulation is stable for at least about 12 months when stored under refrigerated conditions at about 2° C. to about 8° C.
7 . The pharmaceutical formulation of claim 1 wherein
the therapeutic monoclonal antibody is bevacizumab in an amount of from about 10 mg/ml to about 25 mg/ml;
the buffer comprises from about 0.15 mM to about 0.35 mM polysorbate 20, from about 15 mM to about 55 monobasic sodium phosphate monohydrate, and from about 1 mM to about 10 mM of dibasic sodium phosphate dihydrate, and from about 50 mM to about 200 mM of trehalose dehydrate;
the pharmaceutical formulation has a pH of about 6; and
the pharmaceutical formulation is stable for at least about 12 months when stored under refrigerated conditions at about 2° C. to about 8° C.
8 . A method of administering the pharmaceutical formulation of claim 3 comprising producing an aerosol using an inhalation device selected from a soft mist inhalation device and a nebulization device.
9 . A method of administering the pharmaceutical formulation of claim 4 comprising producing an aerosol using an inhalation device selected from a soft mist inhalation device and a nebulization device.
10 . A method of administering the pharmaceutical formulation of claim 5 comprising producing an aerosol using an inhalation device selected from a soft mist inhalation device and a nebulization device.
11 . A method of administering the pharmaceutical formulation of claim 6 comprising producing an aerosol using an inhalation device selected from a soft mist inhalation device and a nebulization device.
12 . A method of administering the pharmaceutical formulation of claim 7 comprising producing an aerosol using an inhalation device selected from a soft mist inhalation device and a nebulization device.
13 . A method for treating lung cancer comprising administering the formulation of claim 1 to a patient by inhalation.
14 . A method for treating lung cancer comprising administering the formulation of claim 3 to a patient by inhalation.
15 . A method for treating lung cancer comprising administering the formulation of claim 4 to a patient by inhalation.
16 . A method for treating lung cancer comprising administering the formulation of claim 5 to a patient by inhalation.
17 . A method for treating lung cancer comprising administering the formulation of claim 6 to a patient by inhalation.
18 . A method for treating lung cancer comprising administering the formulation of claim 7 to a patient by inhalation.
19 . The method of claim 2 , wherein the therapeutic monoclonal antibody is administered in a daily dose ranging from about 1 μg to about 2000 mg per dose.